Physician barriers to incorporating pharmacogenetic treatment strategies for nicotine dependence into clinical practice

Clinical Pharmacology and Therapeutics

Volumn 89, Issue 3, 2011, Pages 345-347

  Schnoll, R A ^a   Shields, A E ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; CATECHOL METHYLTRANSFERASE; CYTOCHROME P450 2A6; CYTOCHROME P450 2B6; DOPAMINE 2 RECEPTOR; NICOTINE; NICOTINIC RECEPTOR; NICOTINIC RECEPTOR ALPHA2; NICOTINIC RECEPTOR ALPHA4; NICOTINIC RECEPTOR ALPHA5; NICOTINIC RECEPTOR BETA2; UNCLASSIFIED DRUG; VARENICLINE;

DOPAMINERGIC SYSTEM; DRUG METABOLISM; GENETIC ASSOCIATION; GENETIC SCREENING; GENETIC VARIABILITY; HEREDITY; HUMAN; NICOTINE REPLACEMENT THERAPY; NOTE; PHARMACOGENETICS; PHYSICIAN; PHYSICIAN SELF-REFERRAL; PRIORITY JOURNAL; SEROTONINERGIC SYSTEM; SMOKING; SMOKING CESSATION; TOBACCO DEPENDENCE; WITHDRAWAL SYNDROME; CLINICAL GENETICS; CLINICAL PRACTICE; GENERAL PRACTITIONER; HEALTH CARE SYSTEM; MEDICAL EDUCATION; REVIEW;

ATTITUDE OF HEALTH PERSONNEL; GENETIC RESEARCH; HUMANS; INDIVIDUALIZED MEDICINE; PHARMACOGENETICS; PHYSICIAN'S PRACTICE PATTERNS; PRIMARY HEALTH CARE; SMOKING; SMOKING CESSATION; TOBACCO USE DISORDER;

EID: 79951790058     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2010.267     Document Type: Note

References (5)

1. Ray, R., Schnoll, R.A. & Lerman, C. Nicotine dependence and pharmacogenetics. In Handbook of Behavioral Medicine (ed. Steptoe, A.) (Springer, New York, 2010).
2. Shields, A.E., Blumenthal, D., Weiss, K.B., Comstock, C.B., Currivan, D., & Lerman, C. Barriers to translating emerging genetic research on smoking into clinical practice: perspectives of primary care physicians. J. Gen. Intern. Med. 20, 131-138 (2005).
3. Shields, A.E., Levy, D.E., Blumenthal, D., Currivan, D., McGinn-Shapiro, M., Weiss, K.B. et al. Primary care physicians' willingness to offer a new genetic test to tailor smoking treatment, according to test characteristics. Nicotine Tob. Res. 10, 1037-1045 (2008).
4. Shields, A.E. & Lerman, C. Anticipating clinical integration of pharmacogenetic treatment strategies for addiction: are primary care physicians ready? Clin. Pharmacol. Ther. 83, 635-639 (2008).
5. Levy, D.E., Youatt, E.J. & Shields, A.E. Primary care physicians' concerns about offering a genetic test to tailor smoking cessation treatment. Genet. Med. 9, 842-849 (2007).